Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension
NCT ID: NCT00366119
Last Updated: 2007-03-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
86 participants
INTERVENTIONAL
2006-06-30
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement
NCT06130124
Ramipril 10 mg/Day Prevention
NCT01053910
A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients
NCT06174766
A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents
NCT00389519
A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients
NCT05450601
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ramipril
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* If differences greater than 20mmHg for SBP and 10mmHg for DBP between both arms are present on 3 consecutive readings
* If differences greater than 20mmHg for SBP and 10mmHg for DBP are present on 3 consecutive readings
* impaired hepatic function
* imapaired renal function
* angioedema
* aortic valvular stenosis or obstrcutive ejection disorder
* primary hyperaldosteronism
* renal transplantation, bilateral renal artery stenosis or unilateral stenosis in a single kidney, hemodialysis
* severe respiratory disease
* congestive heart failure( New York Association functional class Ⅲ or Ⅳ)
* malignant hypertension
* labile angina pectoris or myocardial infarction in the last 3 months before study entry
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pacific Pharmaceuticals
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
HyoSoo Kim, Ph.D in MD
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, 28 Yeongeon-dong, Jongno-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RMN-P01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.